Prelude Therapeutics 

Yahoo Finance • last year

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Incorporated (NASDAQ: PRLD) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Prelude Therapeutics Incorporated (NASDAQ: PRLD) (“Prelude”) on behalf of the company’s investors. Since April 2023, shares of Prelude’s... Full story

Yahoo Finance • last year

Prelude Therapeutics Insiders Are Down US$149k But Regain Some Losses

Insiders who bought US$263.0k worth of Prelude Therapeutics Incorporated (NASDAQ:PRLD) stock in the last year have seen some of their losses recouped as the stock gained 25% last week. The purchase, however, has proven to be a pricey bet,... Full story

Yahoo Finance • last year

Investor Alert: Abbott Cooper PLLC Investigates Prelude Therapeutics Incorporated; Urges Prelude Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Prelude Therapeutics Incorporated (NASDAQ: PRLD) (“Prelude” or the “Company”) on behalf of the Company’s investors. The objective of this investigati... Full story

Yahoo Finance • last year

Q3 2023 Abcellera Biologics Inc Earnings Call

Participants Andrew Booth; CFO; AbCellera Biologics Inc. Carl L.G. Hansen; CEO, President & Chairperson; AbCellera Biologics Inc. Tryn T. Stimart; Chief Legal Officer, Chief Compliance Officer & Corporate Secretary; AbCellera Biologics... Full story

Yahoo Finance • last year

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Prioritization of its first-in-class SMARCA2 degrader and potentially best-in-class CDK9 inhibitor programs for continued clinical development Enters partnership with AbCellera to develop a portfolio of precision ADCs with first program b... Full story

Yahoo Finance • last year

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

WILMINGTON, Del. & VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discov... Full story

Yahoo Finance • last year

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Inc. (NASDAQ: PRLD) and Encourages Investors to Contact the Firm

PHILADELPHIA, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Prelude Therapeutics Inc. (NASDAQ: PRLD) (“Prelude”) on behalf of the company’s investors. Since April 2023, shares of Prelude’s common s... Full story

Yahoo Finance • last year

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare inve... Full story

Yahoo Finance • 2 years ago

Prelude Therapeutics Announces Pricing of Public Offering

WILMINGTON, Del., May 18, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its underwritten public offerin... Full story

Yahoo Finance • 2 years ago

Prelude Therapeutics Announces Launch of Proposed Public Offering

WILMINGTON, Del., May 17, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or the “Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced an underwritten public o... Full story

Yahoo Finance • 2 years ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight abstracts being presented at the American Assoc... Full story

Yahoo Finance • 2 years ago

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluat... Full story

Yahoo Finance • 2 years ago

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment... Full story

Yahoo Finance • 2 years ago

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

WILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration, (FDA) cleared the co... Full story

Yahoo Finance • 2 years ago

Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences

WILMINGTON, Del., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare invest... Full story

Yahoo Finance • 2 years ago

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CD... Full story

Yahoo Finance • 3 years ago

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fu... Full story